{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:35:09Z","timestamp":1783366509680,"version":"3.54.6"},"reference-count":31,"publisher":"Massachusetts Medical Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2023,2,9]]},"DOI":"10.1056\/nejmoa2210699","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T22:01:02Z","timestamp":1675893662000},"page":"511-517","source":"Crossref","is-referenced-by-count":32,"title":["Phase 2 Trial of Difelikefalin in Notalgia Paresthetica"],"prefix":"10.1056","volume":"388","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-7161","authenticated-orcid":false,"given":"Brian S.","family":"Kim","sequence":"first","affiliation":[{"name":"From the Kimberly and Eric J. Waldman Department of Dermatology (B.S.K., M.L.), the Mark Lebwohl Center for Neuroinflammation and Sensation (B.S.K.), the Marc and Jennifer Lipschultz Precision Immunology Institute (B.S.K.), and the Friedman Brain Institute (B.S.K.), Icahn School of Medicine at Mount Sinai, New York; Innovaderm Research, Montreal (R.B.); and Cara Therapeutics, Stamford, CT (K.N., C.M., N.S., A.J., J.C., J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[{"name":"From the Kimberly and Eric J. Waldman Department of Dermatology (B.S.K., M.L.), the Mark Lebwohl Center for Neuroinflammation and Sensation (B.S.K.), the Marc and Jennifer Lipschultz Precision Immunology Institute (B.S.K.), and the Friedman Brain Institute (B.S.K.), Icahn School of Medicine at Mount Sinai, New York; Innovaderm Research, Montreal (R.B.); and Cara Therapeutics, Stamford, CT (K.N., C.M., N.S., A.J., J.C., J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Nograles","sequence":"additional","affiliation":[{"name":"From the Kimberly and Eric J. Waldman Department of Dermatology (B.S.K., M.L.), the Mark Lebwohl Center for Neuroinflammation and Sensation (B.S.K.), the Marc and Jennifer Lipschultz Precision Immunology Institute (B.S.K.), and the Friedman Brain Institute (B.S.K.), Icahn School of Medicine at Mount Sinai, New York; Innovaderm Research, Montreal (R.B.); and Cara Therapeutics, Stamford, CT (K.N., C.M., N.S., A.J., J.C., J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Munera","sequence":"additional","affiliation":[{"name":"From the Kimberly and Eric J. Waldman Department of Dermatology (B.S.K., M.L.), the Mark Lebwohl Center for Neuroinflammation and Sensation (B.S.K.), the Marc and Jennifer Lipschultz Precision Immunology Institute (B.S.K.), and the Friedman Brain Institute (B.S.K.), Icahn School of Medicine at Mount Sinai, New York; Innovaderm Research, Montreal (R.B.); and Cara Therapeutics, Stamford, CT (K.N., C.M., N.S., A.J., J.C., J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilam","family":"Shah","sequence":"additional","affiliation":[{"name":"From the Kimberly and Eric J. Waldman Department of Dermatology (B.S.K., M.L.), the Mark Lebwohl Center for Neuroinflammation and Sensation (B.S.K.), the Marc and Jennifer Lipschultz Precision Immunology Institute (B.S.K.), and the Friedman Brain Institute (B.S.K.), Icahn School of Medicine at Mount Sinai, New York; Innovaderm Research, Montreal (R.B.); and Cara Therapeutics, Stamford, CT (K.N., C.M., N.S., A.J., J.C., J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Jebara","sequence":"additional","affiliation":[{"name":"From the Kimberly and Eric J. Waldman Department of Dermatology (B.S.K., M.L.), the Mark Lebwohl Center for Neuroinflammation and Sensation (B.S.K.), the Marc and Jennifer Lipschultz Precision Immunology Institute (B.S.K.), and the Friedman Brain Institute (B.S.K.), Icahn School of Medicine at Mount Sinai, New York; Innovaderm Research, Montreal (R.B.); and Cara Therapeutics, Stamford, CT (K.N., C.M., N.S., A.J., J.C., J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Cirulli","sequence":"additional","affiliation":[{"name":"From the Kimberly and Eric J. Waldman Department of Dermatology (B.S.K., M.L.), the Mark Lebwohl Center for Neuroinflammation and Sensation (B.S.K.), the Marc and Jennifer Lipschultz Precision Immunology Institute (B.S.K.), and the Friedman Brain Institute (B.S.K.), Icahn School of Medicine at Mount Sinai, New York; Innovaderm Research, Montreal (R.B.); and Cara Therapeutics, Stamford, CT (K.N., C.M., N.S., A.J., J.C., J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Goncalves","sequence":"additional","affiliation":[{"name":"From the Kimberly and Eric J. Waldman Department of Dermatology (B.S.K., M.L.), the Mark Lebwohl Center for Neuroinflammation and Sensation (B.S.K.), the Marc and Jennifer Lipschultz Precision Immunology Institute (B.S.K.), and the Friedman Brain Institute (B.S.K.), Icahn School of Medicine at Mount Sinai, New York; Innovaderm Research, Montreal (R.B.); and Cara Therapeutics, Stamford, CT (K.N., C.M., N.S., A.J., J.C., J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"From the Kimberly and Eric J. Waldman Department of Dermatology (B.S.K., M.L.), the Mark Lebwohl Center for Neuroinflammation and Sensation (B.S.K.), the Marc and Jennifer Lipschultz Precision Immunology Institute (B.S.K.), and the Friedman Brain Institute (B.S.K.), Icahn School of Medicine at Mount Sinai, New York; Innovaderm Research, Montreal (R.B.); and Cara Therapeutics, Stamford, CT (K.N., C.M., N.S., A.J., J.C., J.G.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0305"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.0301a02"},{"key":"e_1_3_5_4_2","first-page":"721","article-title":"Notalgia paresthetica.","volume":"57","author":"\u0160itum M","year":"2018","unstructured":"\u0160itum M, Koli\u0107 M, Franceschi N, Pe\u0107ina M. Notalgia paresthetica. Acta Clin Croat 2018;57:721-725.31168209","journal-title":"Acta Clin Croat"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13853"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30217-5"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/acer.14408"},{"key":"e_1_3_5_8_2","unstructured":"Gardell LR Spencer RH Chalmers DT Menzaghi F. Preclinical profile of CR845: a novel long-acting peripheral kappa opioid receptor agonist. Presented at the 12th World Congress on Pain Glasgow United Kingdom August 17\u201322 2008. poster."},{"key":"e_1_3_5_9_2","unstructured":"O\u2019Connor S Labissiere G Spencer R Chalmers D Menzaghi F. Safety pharmacokinetic and pharmacodynamic profile of CR845 a novel peptidergic kappa opioid agonist in development for the treatment of acute pain and itch. Presented at the 13th World Congress on Pain Montreal August 29\u2013September 3 2010. poster."},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2018.08.044"},{"key":"e_1_3_5_11_2","unstructured":"Kim BS Tamari M Zamidar L et al. Oral difelikefalin reduces pruritus in atopic dermatitis. Presented at the 31st European Academy of Dermatology and Venereology Congress Milan September 7\u201310 2022. abstract."},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912770"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100512"},{"key":"e_1_3_5_14_2","unstructured":"Korsuva (difelikefalin). Stamford CT: Cara Therapeutics 2021 (package insert)."},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.01.006"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab200"},{"key":"e_1_3_5_17_2","unstructured":"Yosipovitch G Awad A Spencer R Munera C Menzaghi F. Efficacy and safety of oral difelikefalin in stage 3-5 chronic kidney disease patients with moderate-to-severe pruritus: an analysis from a randomised placebo-controlled phase 2 trial. Presented at the National Kidney Foundation 2020 Spring Clinical Meetings New Orleans March 25\u201329 2020."},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00100110"},{"key":"e_1_3_5_19_2","volume-title":"MOS Sleep Scale: a manual for use and scoring, version 1.0","author":"Spritzer KL","year":"2003","unstructured":"Spritzer KL, Hays RD. MOS Sleep Scale: a manual for use and scoring, version 1.0. Los Angeles: RAND, 2003."},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14464"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17744"},{"issue":"9","key":"e_1_3_5_22_2","first-page":"e1719","article-title":"Notalgia paresthetica: a novel approach to treatment with cryolipolysis.","volume":"9","author":"Cohen PR","year":"2017","unstructured":"Cohen PR. Notalgia paresthetica: a novel approach to treatment with cryolipolysis. Cureus 2017;9(9):e1719-e1719.29188163","journal-title":"Cureus"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01773-6"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13173"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2022.04.003"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100476"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/120347540100500202"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8488-5"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-014-0093-y"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17030425"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.040"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2020.12.001"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2210699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T23:01:42Z","timestamp":1749682902000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2210699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,2,9]]}},"alternative-id":["10.1056\/NEJMoa2210699"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2210699","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]}}}